Predictive insights into plant-based compounds as fibroblast growth factor receptor 1 inhibitors: a combined molecular docking and dynamics simulation study

References

• Amir, M., Mohammad, T., Prasad, K., Hasan, G. M., Kumar, V., Dohare, R., Islam, A., Ahmad, F., & Imtaiyaz Hassan, M. (2020). Virtual high-throughput screening of natural compounds in-search of potential inhibitors for protection of telomeres 1 (POT1). Jour of Biomolecular Structure & Dynamics, 38(15), 4625–4634. https://doi.org/10.1080/07391102.2019.1682052
   PubMed Web of Science ®Google Scholar
• Andricopulo, A. D., Guido, R. V., & Oliva, G. (2008). Virtual screening and its integration with modern drug design technologies. Current Medicinal Chemistry, 15(1), 37–46. https://doi.org/10.2174/092986708783330683
   PubMed Web of Science ®Google Scholar
• Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T, (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews. Drug Discovery, 20(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z
   PubMed Web of Science ®Google Scholar
• Atilgan, C., Gerek, Z., Ozkan, S., & Atilgan, A. (2010). Manipulation of conformational change in proteins by single-residue perturbations. Biophysical Journal, 99(3), 933–943. https://doi.org/10.1016/j.bpj.2010.05.020
   PubMed Web of Science ®Google Scholar
• Berdigaliyev, N., & Aljofan, M. (2020). An overview of drug discovery and development. Future Medicinal Chemistry, 12(10), 939–947. https://doi.org/10.4155/fmc-2019-0307
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Biovia, D. S. (2017). Discovery studio visualizer. Dassault Syst mes, 936.
   Google Scholar
• Bishayee, A., & Sethi, G. (2016). Bioactive natural products in cancer prevention and therapy: Progress and promise. Seminars in Cancer Biology, 40–41, 1–3. https://doi.org/10.1016/j.semcancer.2016.08.006
   PubMed Web of Science ®Google Scholar
• Bogatyrova, O., Mattsson, J. S. M., Ross, E. M., Sanderson, M. P., Backman, M., Botling, J., Brunnström, H., Kurppa, P., La Fleur, L., Strell, C., Wilm, C., Zimmermann, A., Esdar, C., & Micke, P. (2021). FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. European Journal of Cancer, 151, 136–149. https://doi.org/10.1016/j.ejca.2021.04.005
   PubMed Web of Science ®Google Scholar
• Chen, K., Fan, Y., Gu, J., Han, Z., Zeng, H., Mao, C., & Wang, C. (2020). In vivo screening of natural products against angiogenesis and mechanisms of anti-angiogenic activity of deoxysappanone B 7, 4′-Dimethyl Ether. Drug Design, Development and Therapy, 14, 3069–3078. https://doi.org/10.2147/DDDT.S252681
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• David, C. C., & Jacobs, D. J. (2014). Principal component analysis: A method for determining the essential dynamics of proteins. Protein Dynamics: Methods and Protocols, 1084, 193–226. https://doi.org/10.1007/978-1-62703-658-0_11.
   Google Scholar
• DeLano, W. L. (2002). Pymol: An open-source molecular graphics tool. CCP4 Newsl. Protein Crystallogr, 40(1), 82–92.
   Google Scholar
• Ferreira, L. L., & Andricopulo, A. D. (2019). ADMET modeling approaches in drug discovery. Drug Discovery Today, 24(5), 1157–1165. https://doi.org/10.1016/j.drudis.2019.03.015
   PubMed Web of Science ®Google Scholar
• Golfmann, K., Meder, L., Koker, M., Volz, C., Borchmann, S., Tharun, L., Dietlein, F., Malchers, F., Florin, A., Büttner, R., Rosen, N., Rodrik-Outmezguine, V., Hallek, M., & Ullrich, R. T. (2018). Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene, 37(42), 5682–5693. https://doi.org/10.1038/s41388-018-0380-3
   PubMed Web of Science ®Google Scholar
• Lagunin, A., Stepanchikova, A., Filimonov, D., & Poroikov, V. (2000). PASS: Prediction of activity spectra for biologically active substances. Bioinformatics, 16(8), 747–748. https://doi.org/10.1093/bioinformatics/16.8.747
   PubMed Web of Science ®Google Scholar
• Lionta, E., Spyrou, G., K Vassilatis, D., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Current Topics in Medicinal Chemistry, 14(16), 1923–1938. https://doi.org/10.2174/1568026614666140929124445
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead-and drug-like compounds: The rule-of-five revolution. Drug Discovery Today. Technologies, 1(4), 337–341. https://doi.org/10.1016/j.ddtec.2004.11.007
   PubMedGoogle Scholar
• Lobanov, M. Y., Bogatyreva, N., & Galzitskaya, O. (2008). Radius of gyration as an indicator of protein structure compactness. Molecular Biology, 42(4), 623–628. https://doi.org/10.1134/S0026893308040195
   Web of Science ®Google Scholar
• Maisuradze, G. G., Liwo, A., & Scheraga, H. A. (2009). Principal component analysis for protein folding dynamics. Journal of Molecular Biology, 385(1), 312–329. https://doi.org/10.1016/j.jmb.2008.10.018
   PubMed Web of Science ®Google Scholar
• Malde, A. K., Zuo, L., Breeze, M., Stroet, M., Poger, D., Nair, P. C., Oostenbrink, C., & Mark, A. E. (2011). An automated force field topology builder (ATB) and repository: Version 1.0. Journal of Chemical Theory and Computation, 7(12), 4026–4037. https://doi.org/10.1021/ct200196m
   PubMed Web of Science ®Google Scholar
• Marsh, J. A., & Teichmann, S. A. (2011). Relative solvent accessible surface area predicts protein conformational changes upon binding. Structure, 19(6), 859–867. https://doi.org/10.1016/j.str.2011.03.010
   PubMed Web of Science ®Google Scholar
• Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori‐Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J. (2018). Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Medicine, 7(6), 2641–2653. https://doi.org/10.1002/cam4.1517
   PubMed Web of Science ®Google Scholar
• Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146–157. https://doi.org/10.2174/157340911795677602
   PubMed Web of Science ®Google Scholar
• Mohammad, T., Mathur, Y., & Hassan, M. I. (2021). InstaDock: A single-click graphical user interface for molecular docking-based virtual high-throughput screening. Briefings in Bioinformatics, 22(4), bbaa279. https://doi.org/10.1093/bib/bbaa279
   PubMed Web of Science ®Google Scholar
• Naqvi, A. A., Mohammad, T., Hasan, G. M., & Hassan, M. I. (2018). Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Current Topics in Medicinal Chemistry, 18(20), 1755–1768. https://doi.org/10.2174/1568026618666181025114157
   PubMed Web of Science ®Google Scholar
• Nguyen, P., Tsunematsu, T., Yanagisawa, S., Kudo, Y., Miyauchi, M., Kamata, N., & Takata, T. (2013). The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1. British Journal of Cancer, 109(8), 2248–2258. https://doi.org/10.1038/bjc.2013.550
   PubMed Web of Science ®Google Scholar
• Pace, C. N., Fu, H., Lee Fryar, K., Landua, J., Trevino, S. R., Schell, D., Thurlkill, R. L., Imura, S., Scholtz, J. M., Gajiwala, K., Sevcik, J., Urbanikova, L., Myers, J. K., Takano, K., Hebert, E. J., Shirley, B. A., & Grimsley, G. R. (2014). Contribution of hydrogen bonds to protein stability. Protein Science: A Publication of the Protein Society, 23(5), 652–661. https://doi.org/10.1002/pro.2449
   PubMed Web of Science ®Google Scholar
• Papaleo, E., Mereghetti, P., Fantucci, P., Grandori, R., & De Gioia, L. (2009). Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: The myoglobin case. Journal of Molecular Graphics & Modelling, 27(8), 889–899. https://doi.org/10.1016/j.jmgm.2009.01.006
   PubMed Web of Science ®Google Scholar
• Pires, D. E., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
   PubMed Web of Science ®Google Scholar
• Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., Iravani, M., Fenwick, K., Weber, B., Hardisson, D., Schmitt, F. C., Palacios, J., Lakhani, S. R., & Ashworth, A. (2006). FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(22), 6652–6662. https://doi.org/10.1158/1078-0432.CCR-06-1164
   PubMed Web of Science ®Google Scholar
• Salsbury, F. R. Jr. (2010). Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. Current Opinion in Pharmacology, 10(6), 738–744. https://doi.org/10.1016/j.coph.2010.09.016
   PubMed Web of Science ®Google Scholar
• Shukla, R., & Tripathi, T. (2020). Molecular dynamics simulation of protein and protein-ligand complexes. In D. B. Singh (Ed.), Computer-aided Drug Design (pp. 133–161). Singapore: Springer. https://doi.org/10.1007/978-981-15-6815-2_7
   Google Scholar
• Siricilla, S., Hansen, C. J., Rogers, J. H., De, D., Simpson, C. L., Waterson, A. G., Sulikowski, G. A., Crockett, S. L., Boatwright, N., Reese, J., Paria, B. C., Newton, J., & Herington, J. L. (2023). Arrest of mouse preterm labor until term delivery by combination therapy with atosiban and mundulone, a natural product with tocolytic efficacy. Pharmacological Research, 195, 106876. https://doi.org/10.1016/j.phrs.2023.106876
   PubMed Web of Science ®Google Scholar
• Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
   PubMed Web of Science ®Google Scholar
• Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., Gillett, C., Grigoriadis, A., Tutt, A., Reis-Filho, J. S., & Ashworth, A. (2010). FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Research, 70(5), 2085–2094. https://doi.org/10.1158/0008-5472.CAN-09-3746
   PubMed Web of Science ®Google Scholar
• Turner, P. (2005). XMGRACE, Version 5.1. 19. Center for Coastal and Land-Margin Research. Oregon Graduate Institute of Science and Technology. 2.
   Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
   PubMed Web of Science ®Google Scholar
• Vivek-Ananth, R., Mohanraj, K., Sahoo, A. K., & Samal, A. (2023). IMPPAT 2.0: An enhanced and expanded phytochemical atlas of Indian medicinal plants. ACS Omega, 8(9), 8827–8845. https://doi.org/10.1021/acsomega.3c00156
   PubMedGoogle Scholar
• Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., Moch, H., Wagener, P., Fischer, F., Heynck, S., Koker, M., Schöttle, J., Leenders, F., Gabler, F., Dabow, I., … Thomas, R. K. (2010). Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine, 2(62), 62ra93. https://doi.org/10.1126/scitranslmed.3001451
   PubMed Web of Science ®Google Scholar
• Wu, Y., Tepper, H. L., & Voth, G. A. (2006). Flexible simple point-charge water model with improved liquid-state properties. The Journal of Chemical Physics, 124(2), 024503. https://doi.org/10.1063/1.2136877
   PubMed Web of Science ®Google Scholar
• Yang, F., Zhang, Y., Ressler, S. J., Ittmann, M. M., Ayala, G. E., Dang, T. D., Wang, F., & Rowley, D. R. (2013). FGFR1 is essential for prostate cancer progression and metastasis. Cancer Research, 73(12), 3716–3724. https://doi.org/10.1158/0008-5472.CAN-12-3274
   PubMed Web of Science ®Google Scholar
• Yu, T., Yang, Y., Liu, Y., Zhang, Y., Xu, H., Li, M., Ponnusamy, M., Wang, K., Wang, J.-X., & Li, P.-F. (2017). A FGFR1 inhibitor patent review: Progress since 2010. Expert Opinion on Therapeutic Patents, 27(4), 439–454. https://doi.org/10.1080/13543776.2017.1272574
   PubMed Web of Science ®Google Scholar